C-Kit Kinase Inhibitor Compounds for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds that inhibit KIT, CSF1R, and PDGFR kinases are not approved for treating autoimmune diseases or disorders involving abnormal activation of these kinases.
Innovation Solution
Development of a compound of Formula (I) or its pharmaceutically acceptable salt, which selectively inhibits KIT, CSF1R, and PDGFR kinases, offering potential therapeutic benefits for autoimmune and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current compounds that inhibit KIT, CSF1R, and PDGFR kinases are used, then kinase inhibition activity is achieved, but approval for treating autoimmune diseases has not been obtained
Solution Approach 1:
The patent modifies the chemical structure parameters of existing kinase inhibitors by introducing specific substituent groups (R1, R2, R3, R4, R5) at defined positions in the molecular framework. These structural parameter changes aim to optimize the compounds' pharmacological properties, selectivity, and efficacy for autoimmune disease treatment, thereby achieving therapeutic approval status.
Solution Approach 2:
The patent divides the kinase inhibitor development into specific structural segments with defined substituent positions (R1-R5 groups). By optimizing each segment independently and systematically evaluating their contributions to kinase inhibition and safety profiles, the patent seeks to develop compounds suitable for autoimmune disease indications.
2Reliability
If a compound selectively inhibits KIT, CSF1R, and PDGFR kinases, then therapeutic benefit for autoimmune disorders is provided, but the compound structure becomes more complex
Solution Approach 1:
The patent designs a single molecular framework that can simultaneously inhibit multiple kinases (KIT, CSF1R, and PDGFR). The core structure is engineered to interact with conserved regions across these kinase families, enabling multi-target inhibition with a single compound, thereby achieving broad therapeutic efficacy without proportionally increasing complexity.
Solution Approach 2:
The patent introduces specific substituent groups (R1, R2, R3, R4, R5) at defined positions to modulate the compound's selectivity and potency for different kinases. By optimizing local structural features rather than redesigning the entire molecule, the patent achieves selective inhibition of target kinases while maintaining reasonable structural complexity.
Data Source
AI summary
The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof,which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFRα, PDGFRβ) kinases.